PCSK9 and Hypercholesterolemia: Gain-of-function mutations in PCSK9 lead to an elevation in serum level of PCSK9, LDLR degradation, an increase in serum level of cholesterol, and consequently a higher risk of hypercholesterolemia (Abifadel et al., 2003).